Solange R. Paredes-Moscosso

Dr. Solange R. Paredes-Moscosso

orcid

Research Focus & Metrics

Academic Career Length

12Years (2015-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 May 2017 in OncoImmunology
Verified
Journal Article
Open access
SGSatyen Harish Gohil
Satyen Harish Gohil
SPSolange R. Paredes-Moscosso
Solange R. Paredes-Moscosso
MHMicaela Harrasser
Micaela Harrasser
MVMarzia Vezzalini
Marzia Vezzalini
ASAldo Scarpa
Aldo Scarpa
MPMarco Della Peruta
Marco Della Peruta
We have developed a humanized bi-specific T-cell engager (BiTE) targeting receptor tyrosine kinase-like orphan receptor 1 (ROR1), a cell surface antigen present on a range of malignancies and cancer-initiating cells. Focusing initially on pancreatic cancer, we demonstrated that our ROR1 BiTE results in T cell mediated and antigen-specific cytotoxicity against ROR1-expressing pancreatic cancer cell lines in vitro at exceedingly low concentrations (0.1 ng/mL) and low effector to target ratios. Our BiTE prevented engraftment of pancreatic tumor xenografts in murine models and reduced the size of established subcutaneous tumors by at least 3-fold. To validate its wider therapeutic potential, we next demonstrated significant cytotoxicity against ovarian cancer in an in vitro and in vivo setting and T-cell-mediated killing of a range of histologically distinct solid tumor cell lines. Overall, our ROR1 BiTE represents a promising immunotherapy approach, because of its ability to target a broad range of malignancies, many with significant unmet therapeutic needs.

7 April 2019 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
SGSatyen H. Gohil
Satyen H. Gohil
RERachel Evans
Rachel Evans
MHMicaela Harasser
Micaela Harasser
MEMohamed El‐Kholy
Mohamed El‐Kholy
SPSolange R. Paredes-Moscosso
Solange R. Paredes-Moscosso
ANAmit C. Nathwani
Amit C. Nathwani
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

19 August 2015 in BMC Veterinary Research
Verified
Journal Article
Open access
PDF file
MMMaria Mellinas-Gomez
Maria Mellinas-Gomez
VSVictoria J. Spanswick
Victoria J. Spanswick
SPSolange R. Paredes-Moscosso
Solange R. Paredes-Moscosso
MRMatthew Robson
Matthew Robson
RPR. Barbara Pedley
R. Barbara Pedley
JHJohn A. Hartley
John A. Hartley
Cancer is the leading cause of death in older dogs and its prevalence is increasing. There is clearly a need to develop more effective anti-cancer drugs in dogs. SG2000 (SJG-136) is a sequence selective DNA minor groove cross-linking agent. Based on its in vitro potency, the spectrum of in vivo and clinical activity against human tumours, and its tolerability in human patients, SG2000 has potential as a novel therapeutic against spontaneously occurring canine malignancies. In vitro cytotoxicity was assessed using SRB and MTT assays, and in vivo activity was assessed using canine tumour xenografts. DNA interstrand cross-linking (ICL) was determined using a modification of the single cell gel electrophoresis (comet) assay. Effects on cell cycle distribution were assessed by flow cytometry and measurement of γ-H2AX by immunofluorescence and immunohistochemistry. SG2000 had a multi-log differential cytotoxic profile against a panel of 12 canine tumour cell lines representing a range of common tumour types in dogs. In the CMeC-1 melanoma cell line, DNA ICLs increased linearly with dose following a 1 h treatment. Peak ICL was achieved within 1 h and no removal was observed over 48 h. A relationship between DNA ICL formation and cytotoxicity was observed across cell lines. The formation of γ-H2AX foci was slow, becoming evident after 4 h and reaching a peak at 24 h. SG2000 exhibited significant anti-tumour activity against two canine melanoma tumour models in vivo. Anti-tumour activity was observed at 0.15 and 0.3 mg/kg given i.v. either once, or weekly x 3. Dose-dependent DNA ICL was observed in tumours (and to a lower level in peripheral blood mononuclear cells) at 2 h and persisted at 24 h. ICL increased following the second and third doses in a repeated dose schedule. At 24 h, dose dependent γ-H2AX foci were more numerous than at 2 h, and greater in tumours than in peripheral blood mononuclear cells. SG2000-induced H2AX phosphorylation measured by immunohistochemistry showed good correspondence, but less sensitivity, than measurement of foci. SG2000 displayed potent activity in vitro against canine cancer cell lines as a result of the formation and persistence of DNA ICLs. SG2000 also had significant in vivo antitumour activity against canine melanoma xenografts, and the comet and γ-H2AX foci methods were relevant pharmacodynamic assays. The clinical testing of SG2000 against spontaneous canine cancer is warranted.

1 February 2017 in The Lancet
Verified
Journal Article
Closed access
SGSatyen Gohil
Satyen Gohil
SPSolange R. Paredes-Moscosso
Solange R. Paredes-Moscosso
MHMicaela Harrasser
Micaela Harrasser
ADAndrew Davidoff
Andrew Davidoff
MPMartin Pule
Martin Pule
ANAmit Nathwani
Amit Nathwani

2 December 2016 in Blood
Verified
Journal Article
Open access
SGSatyen Harish Gohil
Satyen Harish Gohil
MPMarco Della Peruta
Marco Della Peruta
SPSolange R. Paredes-Moscosso
Solange R. Paredes-Moscosso
MHMicaela Harrasser
Micaela Harrasser
GCGordon Weng-Kit Cheung
Gordon Weng-Kit Cheung
ANAmit C Nathwani
Amit C Nathwani
Introduction: Receptor Tyrosine Kinase Like Orphan Receptor 1 (ROR1) is a surface antigen expressed on a range of haematological and solid malignancies including Chronic Lymphocytic Leukaemia (CLL). Although expressed during embryogenesis, its virtual absence on normal adult tissues makes it an attractive target for immunotherapy, especially with Chimeric Antigen Receptor modified T-cells (CAR T-cells). We have generated novel fully humanised ROR1CAR constructs for the treatment of CLL and other ROR1 positive malignancies. Results: Following a rat immunisation programme 38 oligloclonal hybridoma clones were single cell sorted and subjected to 5'RACE. Of 13 novel anti-ROR1 antibodies isolated, 10 retained specific binding when cloned into a heavy-linker-light single chain variable fragment (scFv) format. These scFvs in combination with a second generation CAR architecture comprising CD3zeta and 4-1BB demonstrated specific toxicity against ROR1 positive cell lines after T-cell transduction using lentiviral vectors. We found cytotoxicity with ROR1CAR T-cells was dependent on target cell ROR1 density. In order to ensure our screening assays allowed us to select which of the 10 binders was most suitable for targeting primary CLL, we assessed the antigen density of ROR1 and CD19 on CLL cells. Median expression of ROR1 was 2304 molecules/cell (Range 800-4828), compared to CD19, which had a much higher density of 12,583 (Range 5894-23,652). In view of this, subsequent functional assessment was focused on SKW and Jeko1 cell lines with constitutive ROR1 expression at levels similar to CLL cells, as opposed to those transduced to express supra-physiological levels. Our initial optimisation focused on modifying the CAR extracellular spacer region. We demonstrated a reciprocal relationship between cytotoxicity and the distance between T-cells and target cells. This was assessed by using clones that bound either the membrane-distal immunoglobulin domain or a more membrane-proximal frizzled domain of ROR1. The use of an optimum spacer enhanced cytotoxicity of all scFv constructs but yielded two lead candidates: Clones A & F. These showed consistently superior cytotoxicity against target cell lines compared to the other isolated clones. In addition epitope mapping revealed binding sites unique from the previously described rabbit R12 and murine 4A5 anti-ROR1 CAR T-cells. One of the advantages of targeting ROR1 as opposed to CD19 is sparing the normal B-cell compartment from CAR mediated eradication. However this comes with the consequent risk of B-cell mediated immune responses against rat-derived scFvs. To minimise immunogenicity we undertook a humanisation programme and grafted the complementary determining regions (CDR) of the heavy and light chains of Clone A and F into 5 acceptor human germline VH and VL sequences, generating 25 potential scFvs for each. Binding assessment showed seventeen successfully humanised binders for Clone A and three for Clone F. Of these, 5/17 and 3/3 showed activity in a CAR format against target cells. A final selection was made based on specific cytotoxicity, enhanced cytokine secretion (Interleukin-2 and Interferon gamma) and proliferation compared to the parental clones resulting in 2 unique constructs targeting different extracellular domains of ROR1. In addition, we have demonstrated cytotoxicity against a panel of ROR1 positive solid cancer cell lines to demonstrate their wider applicability. Conclusion: ROR1CAR T-cells have the potential to be an effective therapeutic not just for CLL but also Acute Lymphoblastic Leukaemia, Mantle Cell Lymphoma and solid malignancies. We have described the first humanised ROR1 CARs, which target novel epitopes and have proved effective in relevant pre-clinical assays. Although other ROR1 CARs have been described, we believe the unique properties of these constructs merits further investigation and comparison in the preclinical and clinical setting. Disclosures: Gohil: UCL Business: Patents & Royalties: ROR1 based immunotherapies. Della Peruta:UCL Business: Patents & Royalties: ROR1 based immunotherapies. Paredes-Moscosso:UCL Business: Patents & Royalties: ROR1 based immunotherapies. Pule:Roche: Honoraria; UCL Business: Patents & Royalties; Autolus Ltd: Employment, Equity Ownership, Research Funding; Amgen: Honoraria. Nathwani:UCL Business: Patents & Royalties: ROR1 based Immunotherapies.

21 September 2026 in bioRxiv
Verified
Preprint
Open access
PDF file
AMAlan Marín
Alan Marín
LSLuis E. Santos-Rojas
Luis E. Santos-Rojas
RGRenato Gozzer-Wuest
Renato Gozzer-Wuest
AYAngel Yon-Utrilla
Angel Yon-Utrilla
SVSantiago Vigo-López
Santiago Vigo-López
Eliana Zelada-MázmelaEliana Zelada-Mázmela
Eliana Zelada-Mázmela
Batoids (rays, skates, and relatives) are among the most threatened cartilaginous fishes globally, yet the molecular diversity of Peruvian taxa remains poorly evaluated. Furthermore, regional barcode sequences for high-conservation-priority taxa, such as sawfish, manta, and devil rays, are often restricted to private records, hindering essential phylogeographic and population structure assessments. To bridge this gap, we developed BATOseq-PE, the first public genetic reference library for Peruvian marine batoids, covering 14 species sequenced in vitro from local specimens, complemented by a novel in silico assembled mitogenome for Notoraja martinezi . This open-access repository contributes 73 novel COI barcodes, providing robust taxonomic resolution across 15 molecular operational taxonomic units (MOTUs) and Barcode Index Numbers (BINs). Notably, we provide the first Peruvian public records for high-priority species such as Mobula munkiana , Mobula thurstoni , Myliobatis peruviana , Rostroraja velezi , and the first global public barcodes for N . martinezi and Zapteryx xyster . By coupling BATOseq-PE with global datasets, we conducted the first multi-taxa screening for delimitation and phylogeographic assessments on Peruvian rays, revealing a cryptic lineage within R. velezi and genetic connectivity patterns suggesting female philopatry in Mobula mobular . Finally, by integrating nucleotide diversity into a Genetic Diversity Risk Indicator (GDRI) alongside ecological and fishery data, we identified an alarming trend where heavy fishing pressure overlaps with extinction risk and depleted genetic diversity, allowing us to suggest data-driven, tailored management strategies. BATOseq-PE represents a valuable resource to accelerate taxonomic and population assessments, ultimately fostering ray conservation through the integration of genetic frameworks into fishery management.